論文ID: JNMS.2021_88-415
Background: Benefit of chemotherapy for patients with metastatic colorectal cancer is well known, however, that for those patients with poor performance status is little known.
Patients and methods: We retrospectively evaluated efficacy of chemotherapy with capecitabine and bevacizumab for patients with poor PS (PS 3).
Results: Seven patients were included and the median age of the patients was 82 years (range, 65–91 years). The response was not ascertained; nonetheless, the disease control rate was 83.3%. The median PFS and OS were 10.0 and 25.8 months, respectively. Hand foot syndrome (HFS) was the most common toxicity observed (three patients; 42.9%). Grade 3 toxicities were found in one patient with proteinuria and one with hypertension.
Conclusion: This limited study indicated that chemotherapy using capecitabine and bevacizumab for patients with poor PS may provide favorable OFS and OS. Needless to say, we should be careful not to impose extra burden to patients with poor PS.
